Moat

What Protects This Business, If Anything

1. Moat in One Page

Verdict: narrow moat — real, but uneven and segment-specific. ConvaTec sits inside an attractive industry (chronic-care consumables — single-use products that patients reorder every 1–3 days for life, 90%+ reorder rates, 50–70% gross margins across the peer set), but the durable, company-specific advantage shows up in only two of its four franchises. Where it wins, it wins on assets a competitor cannot quickly buy: 180 Medical, the largest US direct-to-patient continence supplier, which now ships 59% of US continence sales as ConvaTec own-brand; and Infusion Care, the only scaled OEM of tubed-pump infusion sets, locked into multi-year contracts with Tandem, Medtronic, and Ypsomed and underwritten by $135–165M of FY2026 growth capex. Where it loses, it loses to scale: ConvaTec is fourth at 6% of the $13.1B Advanced Wound Management market behind Smith+Nephew (14%), Solventum (14%), and private peer Mölnlycke (10%) per SNN's own 2025 disclosure, and #3 in ostomy (~18% share) behind Coloplast (~40%) and Hollister. The structural margin gap to Coloplast (22.3% adjusted vs ~26%; gross margin 56% vs 68%) sets the ceiling on the moat: ConvaTec earns chronic-care economics, but not best-in-class chronic-care economics.

Two pieces of evidence carry the most weight on the bull side: (i) 6.4% organic growth ex-InnovaMatrix in FY2025 is faster than every focused listed peer (Coloplast 4.0%, Solventum 3.3%, SNN AWM 5.6%) and is broad-based across four franchises, not driven by one product; and (ii) the gap to Coloplast on operating margin has halved since 2021 (460 bps closed, ~270 bps to go) — durable advantage shows up first in margin trajectory, and CTEC's is moving in the right direction. The two biggest weaknesses: (a) the January 2026 CMS skin-substitute fee schedule reset — an 80% price cut on InnovaMatrix that erased $50M of FY2026 revenue and forced a $72M impairment — proved the company has limited pricing power against a single-payer rule change, even on a recently acquired premium SKU; and (b) Insulet's tubeless Omnipod grew 24% organic in FY2025 and is taking share of new pump starts, putting a 5–7 year fade timer on the highest-incremental-margin franchise.

Moat Score (1=none, 5=wide)

2

Evidence Strength (0-100)

55

Durability (0-100)

55

Weakest-Link Severity (1=low, 5=high)

2

Verdict: Narrow moat (score 2). Weakest link: Advanced Wound Care scale + biologics LCD risk.

2. Sources of Advantage

This section catalogues every plausible source of advantage and asks: does it hold up under scrutiny? Important terms to anchor the reader: switching costs are the cost, risk, workflow disruption, retraining, or compliance burden a customer faces if they leave; embedded workflow means the product is inserted into a clinician's or patient's daily routine such that change requires re-training; scale economies are unit-cost advantages that grow with volume; regulatory barriers are licences, certifications, or coverage approvals that take years and capital to replicate.

No Results

3. Evidence the Moat Works

A moat that does not show up in business outcomes is a story, not a moat. Below are six pieces of evidence that test whether the alleged sources of advantage translate to actual returns, margins, retention, pricing, share, or cash conversion. The reader should weigh evidence that supports the moat against evidence that refutes it.

No Results
Loading...

Reading the chart: the gap to Coloplast has halved from 1,070bps in 2021 to 370bps in FY2025 — half driven by CTEC margin expansion (FISBE / Accelerate cost programmes), half by Coloplast margin compression (Heylo write-downs, Interventional Urology recall, China dressings return). Half the convergence is CTEC getting better; half is Coloplast losing ground. That nuance matters: a moat that closes only because the benchmark stumbles is not the same as a moat that gains share through superiority.

4. Where the Moat Is Weak or Unproven

This is where a careful analyst pushes back hard. Three weaknesses deserve attention; one is structural, one is segment-specific, one is timing-dependent.

Advanced Wound Care is the structural weakness, not a one-time issue. SNN's 2025 Annual Report quantifies CTEC at 6% of the $13.1B AWM market — fourth behind SNN (14%), SOLV (14%), and Mölnlycke (10%, private). AWC is roughly a third of group revenue, the largest franchise. The brand and clinical heritage that built Aquacel do not translate to scale leadership; they translate to a defensible premium tier inside a market dominated by larger competitors. The structural problem is that the 2026 CMS skin-substitute fee schedule reset ($127.28/cm² in private outpatient offices) just demonstrated how quickly biologic AWC margin pools can be reset by regulator fiat. CTEC has already taken the InnovaMatrix impairment; some peers have not — but the broader read is that biologic AWC is a regulated-margin business, not a moated one. NPWT (~$3.8B by 2030) is similarly hostile: SOLV's V.A.C. is the incumbent, SNN is the credible #2, and CTEC sits sub-scale.

Ostomy is segment-specific weakness, but it is the cash-anchor franchise. CTEC is #3 globally at ~18% share behind Coloplast (~40%) and Hollister (private, top-2). Ostomy demand is the most pricing-power-stable category in chronic care — patients commit for life, payers reimburse predictably — so being #3 means earning #3 economics. The 12-percentage-point gross-margin gap to Coloplast (56% vs 68%) is mostly mix-driven (Coloplast carries ~70% ostomy/continence weighting), and closing it via share gain is the hardest available path. Esteem Body and Natura are credible products; they are not gaining ostomy share against Coloplast at the rate that would close the structural gap.

Insulet is a slow-burn threat to the highest-quality franchise. Infusion Care is the franchise with the cleanest moat (OEM customer locks + capacity-led growth + binding contracts), and PODD is the franchise's biggest threat. PODD revenue grew 24% organic in FY2025 with Omnipod 5 in 19 countries (Type-2 indication added Aug 2024), Omnipod 6 in development, the STRIVE pivotal study completed in 2025, and EVOLUTION 2 enrolling for fully-closed-loop Type-2. Each tubeless patient never buys a CTEC infusion set. The mitigant — that the absolute tubed-pump installed base is still growing — is a 5–7 year story; eventually it crosses over. The moat is real today, but the time-horizon over which it holds is finite.

No Results

5. Moat vs Competitors

Peer comparison is best read as relative durability, not absolute size. The right question is: where does each peer earn its protection, and where is it weak? Most peer data is reasonably well-sourced; private peers (Mölnlycke, Hollister, B. Braun) carry lower confidence because public disclosure is thin.

No Results

Peer-relative moat score by dimension (0 = no presence, 10 = leader)

No Results

Reading the heatmap: CTEC is the leader on two dimensions (Continence DTC and Infusion OEM), competitive on switching costs and brand pipeline, and clearly behind on AWC dressings scale, NPWT, and ostomy share/brand. The aggregate moat score is therefore narrow not wide — the strong dimensions are real but not enough to compensate for sub-scale positions in two of the four franchises.

6. Durability Under Stress

A moat only matters if it survives stress. Below are six stress scenarios drawn from history, peer experience, and current setup. The last column — signal to monitor — converts the analysis into something readable in the next earnings cycle.

No Results

7. Where ConvaTec Group plc Fits

The moat lives in three concentrated places, not evenly across the company. A reader who treats ConvaTec as a single moated chronic-care business is misreading it; the right mental model is "two protected franchises + one platform asset + one structural drag".

No Results

The asymmetric read. Two franchises (Continence + Infusion) carry 40% of revenue and most of the moat. Two franchises (AWC + Ostomy) carry 60% of revenue and the structural drag. Cross-franchise polymer-platform synergy lifts the whole stack, but cannot disguise the sub-scale share in AWM and the #3-not-#1 position in ostomy. The investable thesis is that the protected 40% compounds faster than the unprotected 60% drags — the FY2025 evidence (180 Medical mix at 59%, Infusion +12.5%, broad-based 6.4% organic ex-InnovaMatrix) supports the read but does not confirm it across cycles.

8. What to Watch

The five signals that will tell an investor whether the moat is hardening or fading. Read these every six months at H1 and full-year results.

No Results